CD38 and neoplasm: While CD38 and other metabolic regulators within the TME, such as CD73, have gained traction as novel immunomodulating molecules and, thus, as potential targets for treatment, it remains unclear how inhibition of CD38 in solid tumors may impact anti-tumor immune functionality within these same tumors.